Redmile Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Redmile Group’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-649,446	Closed	-$2.4M	–	79
2017 Q4	$2.4M	Sell	649,446 -1,320,523	-67%	-$5.41M	0.1%	61
2017 Q3	$8.06M	Sell	1,969,969 -1,766,025	-47%	-$6.76M	0.4%	47
2017 Q2	$13.9M	Sell	3,735,994 -336,430	-8%	-$1.33M	0.84%	42
2017 Q1	$16.9M	Buy	+4,072,424	New	+$17.1M	1.09%	35
2016 Q1	–	Sell	-388,550	Closed	-$5.17M	–	64
2015 Q4	$5.17M	Sell	388,550 -213,948	-36%	-$3.68M	0.39%	40
2015 Q3	$9.9M	Sell	602,498 -91,648	-13%	-$1.88M	0.75%	32
2015 Q2	$15.6M	Buy	+694,146	New	+$11M	1.28%	32

Redmile Group's CASC Position: Q1 2018 in Review

Redmile Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 649,446 shares — an estimated $2.4M sold.

Redmile Group first reported a position in CASC in Q2 2015 and held it in 7 quarters. The position peaked at $16.9M in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Redmile Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Redmile Group sold 649,446 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2.4M.
Redmile Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
Redmile Group's Cascadian Therapeutics, Inc. position peaked at $16.9M in Q1 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.